Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 465-472

  Agúndez, José A G ^a   Menaya, Jesús G ^a   Tejeda, Rocío ^a   Lago, Fernando ^a   Chávez, Manuel ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP2D6; Diabetes; Genotype; NAT2

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; DNA;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0029798504     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00011     Document Type: Article

References (69)

1. Agúndez JAG, Martínez C, Ladero JM, Ledesma MC, Ramos JM Martin R, Rodriguez A, Jara C, Benitez J. Debrisoquin oxidation genotype and susceptibility to lung cancer, Clin Pharmacol Ther 1994: 55, 10-14.
2. Agúndez JAG, Ledesma MC, Benitez J, Ladero JM. Rodriguez-Lescure A, Diaz-Rubio M, Diaz-Rubio E. CYP2D6 genes and risk of liver cancer. Lancet 1995a: 345, 830-831.
3. Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, Bernai ML, Molina JA, Ayuso L, Vasquez A, Pavra J, Duarte J, Coria F. Ladero JM, Alvarez-Cermeño JC, Benítez J. Association between the oxidative polymorphism and early onset of Parkinson's disease, Clin Pharmacol Ther 1995b: 57, 291-298.
4. Agúndez JAG, Ladero JM, Olivera M, Abildúa R, Roman JM, Benítez J. Genetic analysis of the arylamine N-acetyltransferase in breast cancer patients. Oncology 1995c: 52, 7-11.
5. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992: 339, 1017-1018.
6. Ayesh R, Smith RL, Genetic polymorphism in human toxicology. In: Turner P, Volans GN, eds. Recent advances in clinical pharmacology and toxicology, number 4. New York: Churchill Livingstone, 1989, 137-157.
7. Ayesh R,. Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984: 312, 169-170.
8. Benítez J, Ladero JM, Jiménez-Jiménez FJ, Martinez C, Puerto AM, Valdivielso MJ, Llerena A, Cobaleda J, Muñoz JJ. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990a: 53, 289-292.
9. Benítez J, Ladero JM, Fernández-Gundin MJ, Llerena A, Cobaleda J, Martinez C, Muñoz JJ, Vargas E, Prados J, Gonzalez-Rozas F. Polymorphic oxidation of debrisoquine in bladder cancer. Ann Med 1990b: 22, 157-160.
10. Benítez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E, Muñoz JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 1991: 27, 158-161.
11. Bertilsson L, Dahl ML, Sjöqvist F, Åberg-Wistedt A, Johansson I, Lundqvist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993: 341, 63.
12. Bonisolli L, Pontiroli AE, de Pasqua A, Calderara A, Maffi P, Gallus G, Radaelli G, Pozza G. Association between chlorpropamide-alcohol flushing and fast acetylator phenotype in Type I and Type II diabetes. Acta Diabet Latino 1985: 22, 303-315.
13. Brøsen K, Gram LF. Clinical significance of the sparteine/ debrisoquine polymorphism. Eur J Clin Pharmacol 1989: 36, 537-547.
14. Bulowvskaya LN, Krupin RG, Bochina TA, Shipova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology 1978: 35, 185-188.
15. Bulpitt CJ. Confidence intervals. Lancet 1987: 1, 494-497.
16. Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic dimorphism according to acetylator status. Br Med J 1978: 1, 208-210.
17. Caporaso NE, Tucker MA, Hoower RN, Hayes RB, Pickle LW, Isaaq HJ, Muschik GM, Green-Gallo L, Buivys D, Aisner S. Lung cancer and the debrisoquine metabolic phenotype. J. Natl Cancer Inst 1990; 82, 1264-1272.
18. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982: 2, 842-845.
19. Chiba K. A susceptible factor to acquire parkinsonism; sparteine oxidation polymorphism. Rinsho Sinkeigaku 1989: 29, 1507-1509.
20. Comella CL, Tanner CM, Goetz C, Gans S, Rapp D, Fischer J. Debrisoquine metabolism in Parkinson's disease. Neurology 1987: 37(S 1), 261-262.
21. Diabetes Survey Working Party. Report of a working party appointed by the Royal College of general Practitioners. Br Mrd J 1962: i, 1479-1503.
22. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism. Clinical aspects. In: Kalow W. ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 625-648.
23. El-Yazigi A, Johansen K, Raines DA, Dossing M. N-acetylation polymorphism and diabetes mellitus among Saudi Arabians. J Clin Pharmacol 1992: 32, 905-910.
24. Evans DAP. Survey of the acetylator polymorphism in spontaneous disorders. J Med Genet 1984: 21, 243-253.
25. Evans DAP. N-Acetyltransferase. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 95-178.
26. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylation phenotype with bladder cancer. J. Med Genet: 20, 330-333
27. Evans DAP, Paterson S, Francisco P, Alvarez G. The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet 1985: 22, 479-483.
28. Forrest RD, Jackson CA, Yudkin JS. Glucose intolerance and hypertension in North London: the Islington diabetes survey. Diabetic Med 1986: 3, 338-342.
29. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Human Genet 1991:48, 943-950.
30. Green A. The role of genetic factors in the development of insulin-dependent diabetes mellitus. In: Baekkeskov S, Hansen B, eds. Current topics in microbiology and immunology. Human diabetes: genetic, environmental and autoimmune etiology. Berlin: Springer Verlag. 1990: 3-16.
31. Haavisto M, Mattila K, Rajala S. Blood glucose and diabetes mellitus in subjects aged 85 years or more. Ac ta Med Scand 1983: 214,239-244.
32. Harkness J. Prevalence of glycosuria and diabetes mellitus. A comprehensive survey in an urban community. Br Med J 1962: i, 1503-1507.
33. Heim M, Meyer UA. Genetic polymorphism of debrisoquine oxidation: Analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods Enzymol 1991: 206, 173-183.
34. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993: 3, 19-27.
35. Irshaid Y, Al-Hadidi H, Abuierjeie M, Latif A, Sartawi O, Rawashdeh N. Acetylator phenotypes of Jordanian diabetics. EurJ Clin Pharmacol 1992: 43, 621-623.
36. Idle JR. Hydroxylation phenotype and hepatocellular carcinoma. In: Davis M, Tredger JM, Williams R (eds). Drug reactions and the liver. London: Pitman Medical 1981: 313-315.
37. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F. Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra-rapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
38. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray W, Branch RA. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987: 47, 5488-5493.
39. Kallio J, Huupponen R, Viikari J. Debrisoquine hydroxylation polymorphism in diabetic patients. Diabetes Res 1990: 15, 125-129.
40. Ladero JM, Arrojo A, de Salamanca RE, Gómez M, Cano F, Alfonso M. Hepatic acetylator phenotype in diabetes mellitus. Ann Clin Res 1982: 14, 187-189.
41. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D, Uson AC. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985: 17, 96-99.
42. Lindsay RM, Baird JD. The effect of diabetes in the in vivo acetylation capacity of the spontaneous diabetic, insulin-dependent BB/Edinburgh Wistar rat. Biochem Pharmacol 1991: 41, 425-430.
43. Lindsay RM, Baty JD. The effect of streptozotocin-induced diabetes on the in vivo acetylation capacity and the in vitro blood N-acetyltransferase activity of the adult male Sprague-Dawley rat, Biochem Pharmacol 1990: 39, 1191-1197.
44. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979: 29, 71-79.
45. Martínez C, Agúndez JAG, Olivera M, Martin R, Ladero JM and Benitez J. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995: 5, 207-214.
46. Mattila MJ, Tiitinen H. The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients. Ann Acad Sci Fenn (Med) 1967: 45, 423-427.
47. McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. Br Med J 1977: 2, 291-293.
48. Mommsen S, Barfod NM, Aagaard J. N-acetyltransferase phenotypes in urinary bladder cancer of a low-risk population. Carcinogenesis 1985: 6, 199-201.
49. Morsiani L, Beretta P, Pareschi PL, Manservigi D, Bottoni L. Longterm results in preventive medicine for type II diabetes. Acta Diabetol Lat 1985: 22, 191-202.
50. Mrozikiewicz PM, Drakoulis N, Roots I, Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1994: 56, 626-634.
51. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986: 73, 320-332.
52. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K. The N-acetyltransferase (NAT) gene: an eary risk marker for diabetic nephropathy in Japanese type 2 diabetic patients? Diabet Med 1994: 11, 783-788.
53. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet 1987: 2, 386.
54. Pozza G, Pappalettera A, Ghidoni A, Tognetti A. Prime considerazioni a proposito di una campagne epidemiologica sul diabete in un comune della provincia de Milano. In: Atti IV Congresso Nazionale SID. Modena: Cooptip. 1972: 549-555.
55. Pozza G, Garancini P, Gallus G. Prevalence and incidence of NIDDM. In: Williams R, Papoz L, Fuller J, eds. Diabetes in Europe. London: John Libbey & Co., 1993: 21-58.
56. Reid DD, Brett GZ, Hamilton PJ. Jarret RJ, Keen H, Rose G. Cardio-respiratory disease and diabetes among middle-aged male civil servants. Lancet 1974: i, 469-473.
57. Shenfield GM, McCan VJ, Tjokresetio R. Acelylator status and diabetic neuropathy. Diabetologia 1982: 22, 221-224.
58. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
59. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Shapira AH, Williams AC, Maranganore DM. Idle JR. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992: 339, 1375-1377.
60. Smith, RL. Polymorphism in drug metabolism - implications for drug toxicity. Arch Toxicol (Suppl) 1986: 9, 138-146.
61. Steiger MJ. Lledo P, Quinn NP, Marsden CD, Turner P. Jenner PG. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992: 86, 159-164.
62. Stroev EA, Belkina ZV. Effect of antidiabetic preparations on the process of xenobiotic metabolism. Farmakol Toksikol 1989: 52, 74-77.
63. Stryjek-Kamisnka D, Malczewski B, Kopec A, Rowinska-Marcinska K. Acetylator phenotype in diabetes mellitus. Acta Diabet Latina 1988: 25, 41-48.
64. Suhardjono D, Boutagy J, Shenfield GM. The effect of glucose on acetylation status. Br J Clin Pharmacol 1986: 22, 401-408.
65. Thom S, Farrow PR, Santoso B, Alberti KG, Rawlins MD. Effect of oral glucose in lime juice on isoniazid kinetics. Br J Clin Pharmacol 1981: 11, 425.
66. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991: 1, 26-52.
67. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Tannenbaum SR. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994: 369, 154-156.
68. WHO Study Group. Diabetes Mellitus. Technical Report Series 727. Geneva, World Health Organization, 1985.
69. Wolf H, Lower GM Jr. Bryan GT. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 1980: 14, 161-165.